Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.87 |
| ▸ | KDR | P35968 | 11/20 | 0.73 |
| ▸ | FLT3 | P36888 | 8/20 | 0.73 |
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18655372 | 0.95 | GSK3B (0.80) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL10069744 | 0.93 | GSK3B (1.00) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL18655375 | 0.92 | GSK3B (0.79) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL18655336 | 0.88 | GSK3B (0.86) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL10070111 | 0.86 | GSK3B (0.68) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL18628480 | 0.86 | GSK3B (0.68) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL8540158 | 0.85 | PIM1 (0.65) | GSK3BCAMK2D | |
| SCHEMBL9955401 | 0.85 | GSK3B (1.00) | GSK3BKDRFLT3QPCT | |
| SCHEMBL18655376 | 0.84 | GSK3B (0.76) | GSK3BKDRFLT3QPCTPLK4 | |
| SCHEMBL12507153 | 0.83 | KDR (1.00) | GSK3BKDRFLT3CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655359-B1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2017-03-22 | — | — | EP | disclosed |
| EP-2655359-B1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-8957103-B2 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8957103-B2 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20130345281-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-12-26 | — | — | US | disclosed |
| EP-2655359-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2474541-A1 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes- Gutenberg-Universität Mainz (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474541-A1 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes- Gutenberg-Universität Mainz (DE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012084683-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084683-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345281-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, IDH1, INMT | GSK3B 3094/4885KDR 861/4885FLT3 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.